header logo image


Page 50«..1020..49505152..6070..»

Archive for the ‘Biotechnology’ Category

Bucks commissioners OK state award of $2 million for Pa. Biotechnology Center expansion – The Intelligencer

Friday, May 19th, 2017

The Bucks County commissioners unanimously approved a $2 million state grant that will aid the expansion of the Pennsylvania Biotechnology Center in Buckingham.

With their vote Wednesday, the commissioners accepted the agreement between the biotechnology center and the state, and agreed to act as the facilitator for the Redevelopment Assistance Capital Program (RACP).

"Every entity that applies for the RACP grant has to have a cooperation agreement with one of the governments to move forward," said Lynn Bush, executive director of the Bucks County Planning Commission. "We are basically the go-between for the company and the state agency."

Plans have been in motion for years to add more laboratory and office space to the Biotechnology Center. The state grant and a $4.6 million federal grant will contribute to the overall costs of the project, estimated between $12 million and $13 million. The remainder willbe financed with a conventional loan awarded by Univest Bank.

"We're thrilled to continue our partnership with the biotechnology center and allow them the opportunity to grow and expand in that area," said Bucks County Commissioner Robert Loughery. "The center has become a real success story for the county and the region."

A groundbreaking ceremony for the expansion was held in April, but actual construction has yet to begin. Before work could begin in earnest, Bush said Thursday afternoon the plans need to go before the Buckingham Board of Supervisors for final land development approval.

The Biotechnology Center is credited with contributing approximately $1.8 billion to the local economy and supporting more than 700 jobs since its creation in 2007. A partnership with the Hepatitis B Foundation and Delaware Valley University started the initiative, but disagreements on the center's management ended the relationship.

The Hepatitis B Foundation bought out the university's interests in the center for $2 million in October, ending the disagreement and restarting the stalled expansion plans.

Read more from the original source:
Bucks commissioners OK state award of $2 million for Pa. Biotechnology Center expansion - The Intelligencer

Read More...

Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now – Zacks.com

Friday, May 19th, 2017

On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI - Free Report) .

Puma Biotechnology is a development-stage biopharmaceutical company focused on the development and commercialization of innovative treatments that enhance cancer care.

The company posted narrower-than-expected loss in the first quarter of 2017. Reported loss of $1.97 per share was also narrower than year-ago figure of $2.19. With no approved products in its portfolio at the moment, the company does not generate revenues yet. The company reported first-quarter results on May 10, 2017.

So far this year, Pumas shares have outperformed Zacks classified Medical-Biomed/Genetics industry. The companys shares have gained 4.1% while the industry registered an increase of 2.2%.

Puma has made significant progress with its lead candidate, neratinib. The candidate is currently under review in both the U.S. and the EU for HER2+ breast cancer. An approval would be a huge boost for the company given the immense commercial potential in the target market.

We note that several additional studies on neratinib targeting different types of breast cancer patient populations are currently underway. During the quarter, Puma presented encouraging data from several ongoing studies on neratinib at the annual meeting of the American Association for Cancer Research (AACR).

Puma also expects to achieve several milestones in the second quarter of 2017. These include additional data from the phase III study on neratinib in third-line HER2-positive metastatic breast cancer patients and data from a phase II study on neratinib in HER2-positive metastatic breast cancer patients with brain metastases.

However, dependence on the successful development of a single candidate may hurt the companys growth prospects in case of any adverse development or regulatory setback.

Moreover, lack of partnership deals could hamper progress of the candidate as the company has no sales, marketing or distribution capabilities.

Zacks Rank & Key Picks

Puma currently carries a Zacks Rank #2 (Buy). Other stocks in the health care sector that warrant a look include Aeglea BioTherapeutics (AGLE - Free Report) , VIVUS, Inc. (VVUS - Free Report) and MEI Pharma, Inc. (MEIP - Free Report) . While Aeglea carries a Zacks Rank #2, VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy). You can see the complete list of todays Zacks #1 Rank stocks here.

Aegleas loss per share estimates narrowed from $3.64 to $2.48 for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20.75%.

VIVUSs loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233.69%.

MEI Pharmas posted positive earnings surprises in three of the four trailing quarters with an average beat of 66.56%. The companys shares gained 16% so far this year.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Here is the original post:
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now - Zacks.com

Read More...

Puma Biotechnology, Inc. (PBYI): Some of the key technical areas – USA Commerce Daily

Friday, May 19th, 2017

USA Commerce Daily
Puma Biotechnology, Inc. (PBYI): Some of the key technical areas
USA Commerce Daily
With all other things going on, Puma Biotechnology, Inc. (NASDAQ:PBYI) has been on a free fall declining -4.23 percent in just three months. It looks like traders are not happy with the stock. On the other side, analysts now consider Puma ...

and more »

Read more:
Puma Biotechnology, Inc. (PBYI): Some of the key technical areas - USA Commerce Daily

Read More...

Global Biotechnology Congress 2017 – Corporate Registration … – Business Wire (press release)

Friday, May 19th, 2017

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Biotechnology Congress 2017 - (5th in the Series) Corporate" conference to their offering.

The 'Global Biotechnology Congress 2017' would provide eminent scientists the opportunity to present their cutting edge researches in the field of biotechnology and its applications in medicine. A number of Nobel Laureates and leading researchers are expected to participate in this important conference.

This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Many Nobel Laureates and world's renowned experts will participate in the conference.

The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include major research advances in biotechnology, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research.

Throughout the course of the four day conference, you will have the opportunity to both network and hear leaders from the international academic and corporate biotechnology communities.

Benefits of Attending

- Exchange ideas and network with leading biotechnologists and decision makers.

- Bring together top international biotechnology professionals presenting cutting-edge discoveries, research and opportunities for new biotech business practices and partnerships.

- Participants can gain direct access to a core audience of biotechnology professionals and decision makers, and have increased visibility through branding and networking at the conference.

- Obtain a global roundup of Pharmaceutical research capabilities and opportunities.

- The conference will feature a commercial exhibition and poster sessions.

For more information about this conference visit http://www.researchandmarkets.com/research/k2mmsx/global

Read more:
Global Biotechnology Congress 2017 - Corporate Registration ... - Business Wire (press release)

Read More...

Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) – StockNewsJournal

Friday, May 19th, 2017

GuruFocus.com
Digging Up the Facts on Puma Biotechnology, Inc. (PBYI)
StockNewsJournal
Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $36.25, up from yesterday's close by 13.46%. Given the stock's recent action ...
Coherus Biosciences Inc (CHRS) Given a $43.00 Price Target by Maxim Group AnalystsBNB Daily (blog)

all 78 news articles »

Read more:
Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) - StockNewsJournal

Read More...

Planda Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes – Markets Insider

Friday, May 19th, 2017

NEW YORK, NY--(Marketwired - May 18, 2017) - Planda Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable green tea extract, Phytofare Catechin Complex, to regulate blood glucose levels in type 2 diabetics. If the positive data that was recently published in the Journal of Human Nutrition and Dietetics is any indicator, Planda should expect to receive its own positive data. The two studies could complement one another, and Planda's study could further strengthen the case for using green tea catechins in improving the health of type 2 diabetics.

According to an industry report, the market for diabetes drugs alone was valued at $30.95 billion in 2016, and it's expected to grow at an exponential rate and become a $44.53 billion market by 2021, at a CAGR of about 7.5%.

Obviously Planda would like to carve out its own space in this industry, and with a recently published study showing success with a green tea supplement that only contained 1 of the tea plant's 8 catechins, Planda has to feel pretty confident it can produce even better data given it can deliver all 8 catechins with its Phytofare extract.

Catechins are known as antioxidants, and antioxidants protect the body from free radicals that are thought to play a role in everything from heart disease to cancer. Catechins are found in the greatest abundance in the leaves of the tea plant.

And we already know that Planda produces a product (Phytofare) that contains all 8 of the catechins found in the tea plant. But, more importantly, Planda's product has proven in human clinical trials that it can deliver 10 times more of the catechins into the bloodstream and keep those antioxidants there at therapeutic levels for more than 24 hours.

Now, let's fast forward to the data from a study that was just published in the Journal of Human Nutrition and Dietetics and how Planda can add to that data with its clinical trial in diabetes. In that clinical trial, over 400 pregnant women, all of whom were in their third trimester and were diagnosed with gestational diabetes mellitus or "GDM," participated in investigating the effects of the catechin "epigallocatechin 3-gallate" (EGCG) on GDM in terms of both maternal and neonatal treatment outcomes.

Data from the study suggests that mothers with GDM, who were given EGCG as a supplement during the third trimester of their pregnancy, had significantly improved maternal diabetic parameters, and fewer cases of neonatal complications, compared to similar women given a placebo supplement.

One of the trial's authors, H. Zhang, said of the study, "Our current clinical trial is the first to report the potential therapeutic value of the natural compound EGCG in GDM, which is able to both alleviate maternal diabetic symptoms and reduce the incidence of neonatal complications."

A point that we can't emphasize enough from the GDM study that could benefit Planda greatly is that participants were given a supplement that contained only 1 of the 8 catechins, and we don't even know how bioavailable the supplement was. During Planda's clinical trial however, participants will be given Phytofare, which we know will deliver all 8 catechins into the bloodstream of each participant in the study. So we expect that Planda's data could be extremely positive and further strengthen the research done in the GDM study.

Given how potent Phytofare is, and how Planda is able to enhance the already highly bioavailable extract even more by entrapping it in liposomes, positive data from Planda's upcoming clinical trial in type 2 diabetes could thrust the company into the conversation, and become a real solution for how we're treating/managing type 2 diabetes worldwide.

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: http://www.stockmarketmediagroup.com.

Go here to see the original:
Planda Biotechnology's Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes - Markets Insider

Read More...

Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment – Business Wire (press release)

Thursday, May 18th, 2017

VANCOUVER, British Columbia--(BUSINESS WIRE)--Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with The Centre for Drug Research and Development (CDRD), Canadas national drug development and commercialization centre, to further characterize Novelogics' internally-developed antibody immunotherapy for treating cancer.

The proprietary technology behind Novelogics innovation involves discovery and development of monoclonal antibodies that target a protein that promotes immune suppression in cancer patients. It is predicted that this new therapy could treat a broad range of cancers, and because it works with the patients own immune system, it would be safer and less toxic with fewer debilitating side-effects.

CDRD will be analyzing the technology through custom in vitro assays that will help validate and identify their lead antibody and move it towards a Phase 1 clinical trial as early as 2019. The technology has recently shown preliminary evidence of tumour inhibition in a prostate cancer model and based on results from CDRDs research, it could be expanded to other cancer models.

Novelogics President and Chief Scientific Officer Dr. Wayne Cheney stated, We are excited to introduce our novel approach to treating cancer. Unlike other immunotherapies that function by modulating, inhibiting or blocking targets, our innovative drug works by intercepting. This is a new way of limiting the immune suppressive effects of the drug target, which offers a huge opportunity to make a difference in the fight against cancer. We look forward to a successful collaboration with CDRD and are thrilled to be working with their technical team of experts and state-of-the-art biologics facility.

CDRDs Head of Biologics Dr. Ismael Samudio commented, This work with Novelogics is an exciting opportunity for CDRD to apply our scientific expertise in NK cell biology and therapeutic antibodies to a technology that has very promising pre-clinical potential. This a great example of how CDRD is partnering with Canadian life sciences companies to advance promising discoveries and transform them into validated investments and improved health outcomes. By combining our expertise and specialized infrastructure, we aim to provide critical data to advance Novelogics technology and help bring new therapeutic treatments to market.

It is anticipated that a pre-clinical candidate antibody will be selected in 2017, and that further clinical development activities will follow.

About Novelogics Biotechnology, Inc.

Novelogics Biotechnology Inc. is virtual life sciences company utilizing expertise at a variety of Contract Research labs and is dedicated to developing innovative cancer treatments that harness the power of the immune system to help eradicate tumors more naturally. Their immunotherapy concepts focus on development of antibody therapeutics and have the potential to treat multiple cancer types without the side-effects associated with traditional cancer therapies. We anticipate the technology will be well-received by larger biotechnology and pharmaceutical companies seeking novel antibody immunotherapy treatments in this exciting area of cancer drug development. Novelogics has one mission in mind we want to create better cancer treatments. http://www.novelogics.com

Novelogics Biotechnology Inc. is a privately-owned corporation operating in Vancouver, Canada.

About The Centre for Drug Research and Development (CDRD)

CDRD is Canadas national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. Canadas Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). http://www.cdrd.ca

Read more:
Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment - Business Wire (press release)

Read More...

Forge Therapeutics Attracts Biotechnology Leaders To Join Expanded Board Of Directors – PR Newswire (press release)

Wednesday, May 17th, 2017

"Forge is a very exciting, emerging life science company its novel platform and programs, its highly efficient business model, and its creative capitalization all attracted me to join the Board at such a pivotal time in the company's evolution," said John Schmid. "I look forward to providing strategic, operational and financial guidance to the management team in the coming years."

Dr. Worland added, "Multi-drug resistant bacteria 'superbugs' pose a very serious threat to human health and Forge's novel antibiotic program provides a promising solution to this global problem. I am honored to join the Forge Board and excited to work with its talented management team, advisors, and alliance and government partners as the company and technology platforms mature."

About the Forge Board of Directors

Forge's Board of Directors is a well-balanced composition of San Diego biotechnology industry veterans, global drug development experts and corporate finance leaders.

About Forge Therapeutics

Forge Therapeutics is a privately-held biopharmaceutical companydeveloping novel antibiotics to treat multi-drug resistant bacteria, or 'superbugs,' that have ignited a global health epidemic. With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes. Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow. Forge has discovered novel small molecule inhibitors of LpxC that are potentin vitro, efficaciousin vivo, and effective against drug resistant Gram-negative bacteria 'superbugs.' To complement its innovative approach to drug discovery, Forge hasa capital efficient business model that utilizes a mix of non-dilutive and traditional funding sources to advance itsprograms, including LpxC. Forge has formed a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards to address the global 'superbug' epidemic. In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its technology and pipeline. For further information, please visit the company's websitewww.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.

Forge Company Contact:Info@ForgeTherapeutics.com

Forge Media Contact:Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-attracts-biotechnology-leaders-to-join-expanded-board-of-directors-300458043.html

SOURCE Forge Therapeutics, Inc.

Home

Read more from the original source:
Forge Therapeutics Attracts Biotechnology Leaders To Join Expanded Board Of Directors - PR Newswire (press release)

Read More...

When OFAB gathered professionals for biotechnology – NIGERIAN TRIBUNE (press release) (blog)

Wednesday, May 17th, 2017

Dr Rose Gidado

Biotechnology is a modern science tool used by most countries to improve agricultural productivity, thereby eliminating hunger and ensuring food security for their populace.

Genetically Modified Organisms (GMOs) is one of the components of biotechnology which is a science tool used to engineer the genes of plants to make them behave in the manner of which they were engineered for.

GMOs have become a topical issue in Nigeria since the country have had problem of providing enough food for the populace. Recently, famine was reported to have reached some parts of the northern Nigeria.

In the quest to ensure food security in the country, some experts have called on the Nigerian government to adopt the new technology of GMOs to increase productivity.

In Nigeria, GMOs have received some criticisms from some groups, arguing the safety of the crops which the genes have been engineered.

Meanwhile, some scientists have said that the GM seeds are like other conventional seeds and does not contain any harmful or toxic contents.

Recently, the Open Forum of Agricultural Biotechnology (OFAB) gathered professionals to brainstorm on how best to convey the message of science to Nigerians.

In Nigeria, farmers who will be the users of this technology if it is adopted in the country are yet to know about the technology, most of them have not heard of the technology.

The Country Coordinator of OFAB, Dr Rose Gidado during the Agricultural Biotechnology and Biosafety Workshop for Professional Bodies Cadre, said the Forum had carried the biotechnology campaign to farmers.

She said the workshop is expected to expand the scope of OFAB and build the capacity of the participants, so that they can understand what the biotechnology is all about.

According to her the objective of the workshop is that we are trying to expand our scope, we are trying to build the capacity of the participants because science is multi faceted, so they need to understand better what we are doing so that they can join in the campaign for GMOs in Nigeria.

Gidado also said that other professional bodies are needed in the campaign, having in mind the huge benefits of this technology to Nigerian populace and the economy.

We need other professional bodies to join us in this campaign because it is all about science. This technology is all about science, it is evidence based, it is important, it can contribute to the socio-economic of Nigeria.

Meanwhile, the Director-General of the National Agricultural Seed Council, Dr Philip Ojo said before the introduction of any Genetically Modified seeds, the local capacity needs to be built.

In this light, the National Biotechnology Development Agency (NABDA), had recently trained about 20 staff of the National Agricultural Seed Council on how to identify or detect GMOs.

The Director General of NABDA, Professor Lucy Ogbadu said Nigeria cannot afford to ignore the technology, adding that another technology which may be more acceptable to Nigerians have been discovered.

She said the new technology which is called gene editing allows the scientist to work within the confines of one genetic material instead of transferring genes from one organism to another.

We cannot afford to ignore this technology, in fact, so much advances have gone beyond where we started on genetic modification, they developed what is called gene editing and we hope that gene editing will be more acceptable to Nigeria.

Explaining what gene editing is, Professor Ogbadu said we are working within the confines of the genetic materials of one organism; we are not bringing in anything from outside into the organism, so we hope that this will be more acceptable to our people.

On the acceptability of the technology, Dr Gidado said the acceptance level in Nigeria is encouraging, more people are talking for the technology, people are beginning to see why we need it.

She further said that they are carrying the farmers along in their campaign, adding that in 2 or 3 years time, the commercialisation of BT cotton and BT cowpea will commence.

One of the environmental advantage of this technology is that less chemicals and pesticides will be used in the farm, leading to less pollution of the environment with fertilizers and chemicals.

Professor Ogbadu in her presentation a the workshop said the technology has increased environmental protection through the reduced use of pesticides and toxic chemicals.

She also said GMOs improves nutrition for people, increase quality of yields, increase farm profitability through reduced cost and new product opportunity.

Much have been said about this technology, some countries have adopted this technology and used it to advance their food production. It is important that the Nigerian government look for other means to upscale our food production.

GMOs among other biotechnology is a scientific method to improve food production in Nigeria, increase yield and practice agriculture as a business, which will in turn put money in the bags of farmers and contribute the nations GDP.

Link:
When OFAB gathered professionals for biotechnology - NIGERIAN TRIBUNE (press release) (blog)

Read More...

iShares Nasdaq Biotechnology Index (ETF) (IBB): The Quick Guide to IBB – Investorplace.com

Tuesday, May 16th, 2017

Biotechnology is one of the more tempting and complex areas of the broader healthcare sector investing. However, stock-picking in this space is tricky, which has made biotechnology exchange-traded funds popular with investors. The most popular as well as the largest biotechnology ETF is the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB).

The $8.2 billion IBBtracks the Nasdaq Biotechnology Index. The funddebuted in 2001, and currently holds 162 stocks.

While IBB has a deep bench relative to other biotechnology ETFs, investors should look under the hood to ensure this is the type of biotech fund they want to be involved with.

For example, investors often hear about biotechnology stocks that deliver jaw-dropping short-term gains on the back of favorable Food & Drug Administration (FDA) news. Then there are the biotechcompanies that are able to prove durable over time, delivering stellar returns for investors for years on end.

While it is hard to say biotechnology is a sector for conservative investors, given the historical volatility associated with the group, IBB can be viewed as one of the more conservative biotechnology ETFs due to its emphasis on the groups biggest names.

IBB is a cap-weighted ETF and as such allocates significant percentages of its weight to the biggest biotechnology names. For example, Celegene Corporation(NASDAQ:CELG), Gilead Sciences, Inc. (NASDAQ:GILD), Biogen Inc(NASDAQ:BIIB) and Amgen, Inc. (NASDAQ:AMGN) combine for nearly 31% of IBBs roster as of this writing.

Another issue to consider with IBB and biotech stocks is that the sector historically trades at valuations that are in excess of that of the healthcare sector and the broader market. Even when biotechnology is cheap by its standards, the group is likely still pricier than healthcare and broader equities benchmarks.

Volatility is also a consideration, as biotechnology stocks are more volatile than the healthcare sector. IBBs three-year standard deviation is 24.2% compared to an equivalent healthcare ETF from the iShares roster with a three-year standard deviation of 13.1%, according to issuer data.

Helped by its emphasis on large-cap biotechnology stocks, the ETF is heavily traded, sports robust liquidity and tight spreads. Those factors help minimize transaction costs and total cost of ownership.

IBB also charges 0.47% per year, or $47 annually on a $10,000 investment.

As of this writing, Todd Shriber did not hold a position in any of the aforementioned securities.

Original post:
iShares Nasdaq Biotechnology Index (ETF) (IBB): The Quick Guide to IBB - Investorplace.com

Read More...

BIO Statement on the Passing of Biotechnology Giant Henri Termeer – Business Wire (press release)

Tuesday, May 16th, 2017

WASHINGTON--(BUSINESS WIRE)--Henri Termeer, who passed away at the age of 71, was a founding father of modern biotechnology. He brought to his work, and to his life, a passion, a vision and a perseverance to bring ground-breaking medical innovations to those suffering from rare diseases.

Through his work, Termeer became a mentor and a role model for biotechnology entrepreneurs around the globe. The culture he created at Genzyme, and at the various institutions he worked for throughout his career, was widely seen as the gold standard for patient-focused drug development. He was a master at creating cultures where great science and great people could flourish. As the Boston Globe aptly noted, Termeer had magnetism and warmth, and a deft ability to harness top talent toward a common goal.

Termeer, who was a larger-than-life figure across the biotechnology field, was instrumental in the founding of BIO in 1993, serving as its first vice chair for health. He was named Chairman of the organization in 1996. During his tenure as Chair of BIO, and in the years that followed, Termeer was a key catalyst in the growth of the organization and in establishing BIOs position at the forefront of key policy and regulatory debates. He was an active member of BIOs Board of Directors since its founding until his death, with only a short break in his tenure. Termeer served on BIOs Executive Committee from 1993 to 2000.

Following are statements from leadership at the Biotechnology Innovation Organization (BIO):

Few people in our industry have had as profound an impact as Henri Termeer on the science of biotechnology and the patients who depend on it, said Jim Greenwood, President and CEO of BIO. He had a unique ability to inspire the men and women around him. Henri certainly was a brilliant businessman and a charismatic leader, but his burning passion was to do the unthinkable to innovate and to treat and cure rare diseases that others believed too difficult to tackle. Henri's love of his profession and the people in it was contagious. He taught us that even though our companies were sometimes competitors, our industry must speak with a united voice in the corridors of power. He was a founding father of BIO and thus the thriving ecosystem the biotechnology community enjoys today is another central part of his legacy. Henri was admired, respected and loved by all of us who were fortunate enough to know him as a colleague, a teacher, and a friend. He is an irreplaceable talent who will be long remembered and sorely missed.

Henri Termeer was a giant, said Ron Cohen, President & CEO of Acorda Therapeutics and Chair of BIO. He has left us much too soon. High among his many legacies are the tens of thousands of patients and their families who have benefited from Genzymes innovations, and the scores of biotechnology professionals whom he mentored and who have gone on to be leaders at other companies.

I had the honor of having worked at Genzyme and calling Henri Termeer amentor, said Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Vice Chair of BIO. He taught us all to be tough and business minded, while simultaneously taking into account how every decision impacted every person in the organization that was part of making Genzyme what it was. His focus on always doing the right thing for people and the business was something truly special. We all lost a great friend, a great mentor and awonderful role model.

From 1993-1998, Hastings served as Vice President, Global Marketing, Genzyme Therapeutics, President of Genzyme Europe and President of Genzyme Therapeutics.

"Henri has left us far too soon, but his legacy and contributions to our industry and patients with rare diseases will last forever, said John Maraganore, CEO of Alnylam Pharmaceuticals. Indeed, Henri pioneered the advancement of innovative medicines for orphan disease and inspired other companies and entrepreneurs to follow. He will be deeply missed."

"As an industry leader Henri was unparalleled and unrivaled, said Jeremy Levin, chairman and CEO of Ovid Therapeutics. As a mentor and friend, he was a foundational component of my business philosophy and career. He will be mourned and deeply missed but never forgotten."

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

Originally posted here:
BIO Statement on the Passing of Biotechnology Giant Henri Termeer - Business Wire (press release)

Read More...

Panel Woes For Puma And Statistical Uncertainties For Emmaus – Seeking Alpha

Monday, May 15th, 2017

Welcome to your weekly digest of approaching regulatory and clinical readouts. Puma's (NYSE:PBYI) breast cancer project neratinib will go before a US panel on May 24, but Roche's (OTCQX:RHHBY) rival Perjeta could soon show clinical data that render neratinib almost irrelevant, and the recent departure of a senior member of Puma's staff has fueled rumors of a negative outcome at the adcom.

On the same day Emmaus Life Sciences will go before the same FDA panel for its sickle cell disease project Endari, currently availbale as a nutraceutical. Regulators have questioned the efficacy analysis in the past, but with few options for patients approval could still ensue.

Puma becomes the prey

In just over a week a panel will discuss Puma's neratinib for use as an adjuvant treatment in Her2-overexpressing breast cancer. The filing was based on the phase III Extenet trial, in which patients received neratinib monotherapy after a year's Herceptin.

Puma has a number of hurdles in its path, the biggest of which is Perjeta. A positive result in Roche's phase III Aphinity study indicated that Perjeta could potentially be practice-changing for breast cancer, and Puma's shares dropped 14% (Aphinity all but confirms Puma's worst nightmare, March 2, 2017).

Roche's trial gave patients Perjeta plus Herceptin for a year versus Herceptin alone. Details, including the extent of Perjeta's benefit, will appear at Asco on June 5.

Other issues for Puma include the severe diarrhea seen with neratinib, questions over neratinib's marginal benefit in Extenet trial, and large numbers of patients being censored.

This week Puma shares took another tumble on the news that its senior vice-president of regulatory affairs, Dr. Robert Charnas, would step down. Speculation that the resignation could be linked with the upcoming panel meeting, rather than the health reasons cited in the company's 8-K, caused shares to fall 16%.

Neratinib sales are forecast to reach $809m by 2022, according to sellside consensus from EvaluatePharma, but just over a year ago these sat at $2bn. Neratinib's PDUFA date is set for July; a strong benefit with Perjeta could be hard for the FDA to ignore.

Lacking options

Emmaus Life Sciences' Endari, in sickle cell disease, will also face the panel on May 24, and has a PDFUA date set for July 7.

The Californian group says that if Endari is approved it will become the first treatment for pediatric patients and the first new therapy in nearly 20 years for adult patients. However, it does not treat the underlying cause of the disease, instead aiming to reduce the frequency of the episodes of pain called sickle cell crises. It has orphan drug designation in the US and EU and US fast-track designation.

Endari is said to work by reducing oxidative damage to red blood cells. It consists of the amino acid L-glutamine as a nutritional supplement - the same active ingredient as the company's Nutrestore nutraceutical, available for short bowel syndrome in combination with recombinant human growth hormone. Endari is filed as a drug under the 505(b)(2) pathway.

The phase III trial was conducted in 230 patients aged five and over. It tested 0.3g/kg of L-glutamine twice daily for 48 weeks, up to a daily limit of 30g. The powder is mixed with water or certain non-heated foods.

The placebo comparator was the food additive maltodextrin, and two thirds of patients were on background hydroxyurea treatment, an established drug used to reduce crises. The company reported a 25% reduction in the median frequency of sickle cell crises, with Endari patients having a median of three over the 48-week trial.

Initially the company reported a p value of 0.063, above the pre-specified p value of 0.045. However, using a different analysis it said the results were "highly statistically significant" at 0.005.

The FDA had raised concerns over the primary endpoint analysis after the data were initially unblinded in 2014. Emmaus provided a report by an independent statistician explaining the significant results using the modified Ridit method, adjusting for varying strata or subgroup size, which in this case was region and hydroxyurea use.

No doubt the panel meeting will pay close attention to the statistical analyses used.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Read more here:
Panel Woes For Puma And Statistical Uncertainties For Emmaus - Seeking Alpha

Read More...

Royal Bank of Canada Reiterates $40.00 Price Target for Puma Biotechnology Inc (PBYI) – The Cerbat Gem

Monday, May 15th, 2017

The Cerbat Gem
Royal Bank of Canada Reiterates $40.00 Price Target for Puma Biotechnology Inc (PBYI)
The Cerbat Gem
Puma Biotechnology Inc logo Royal Bank of Canada set a $40.00 target price on Puma Biotechnology Inc (NYSE:PBYI) in a research note published on Wednesday morning. The firm currently has a hold rating on the biopharmaceutical company's stock.
91 institutional investors are raising stakes in Puma Biotechnology, Inc. (PBYI)Post Analyst
The 260817 Shares in Puma Biotechnology Inc (PBYI) Acquired by Emerald Mutual Fund Advisers TrustBangaloreWeekly
Well recognized Stock of Market: Puma Biotechnology, Inc.'s (PBYI ...Hot Stocks Point
Rives Journal
all 6 news articles »

Read more:
Royal Bank of Canada Reiterates $40.00 Price Target for Puma Biotechnology Inc (PBYI) - The Cerbat Gem

Read More...

At the Focal Point, Checking in on Prana Biotechnology Limited (NASDAQ:PRAN) – Morgan Research

Sunday, May 14th, 2017

Prana Biotechnology Limited (NASDAQ:PRAN) are being monitored closely by investors today as the name is currently priced at$2.22, a-1.77% difference from where it most recently opened. So where is the stock headed from here? We will take a quick look here at how the stock has performed recently.

Most investors are likely looking for that next stock that is ready to take off running. Maybe the focus is on finding a stock that has recently taken a turn for the worse for no real apparent reason. As we all know, as quickly as a stock can drop in price, it can bounce back just as fast.

Although the popular stocks that receive a high level of media coverage tend to recover quicker after a sell-off, there may be plenty of under the radar stocks that are ripe for buying. Scoping out these potential market gems may help repair a portfolio that has taken a hit for any number of reasons.

Is Prana Biotechnology Limited Ready to Move higher? Sign Up For Breaking Alerts on this Stock Before the Crowd.

The average investor might not have the time to monitor every single tick of a given stock, but taking a look at historical performance may help provide some valuable insight on where the stock may be trending in the future. Over the past week, Prana Biotechnology Limited (NASDAQ:PRAN) has performed -9.76%. For the past month, shares are -22.38%. Over the last quarter, shares have performed -2.20%. Looking back further, Prana Biotechnology Limited stock has been -10.48% over the last six months, and 36.20% since the start of the calendar year. For the past full year, shares are -39.01%.

There is rarely any substitute for diligent research, especially when it pertains to the equity markets. No matter what strategy an investor employs, keeping abreast of current market happenings is of the utmost importance. Everyone wants to see their stock picks soar, but the stark reality is that during a market wide sell-off, this may not be the case. Recently, shares of Prana Biotechnology Limited (NASDAQ:PRAN)have been seen trading -29.89% away from the 200-day moving average and -14.88% off the 50-day moving average. The stock is currently trading -66.82% away from the 52-week high and separated 46.05% from the 52-week low. Prana Biotechnology Limiteds RSI is presently sitting at 34.71.

New investors may sometimes be working with limited capital. Choosing which stocks to own can be a tough decision. Individuals may be deciding on whether to buy 10 shares of a stock trading at $100 as opposed to purchasing 100 shares of a stock trading at $10. We have recently been focusing on stocks that are trading under the $10 price level. We are constantly monitoring technical and fundamental factors that may lead to breakouts for these relatively cheap (in terms of price) stocks.

Go here to read the rest:
At the Focal Point, Checking in on Prana Biotechnology Limited (NASDAQ:PRAN) - Morgan Research

Read More...

Biotechnology dept to set up tissue culture lab – Millennium Post

Wednesday, May 10th, 2017

The state Biotechnology department has decided to set up a state-of-the-art plant tissue culture laboratory at the Kolkata Biotech Park to enhance production and quality of plants and vegetables.

There will be scientists and research fellows who will carry out various kinds of research on plants and bio-fertilizers and how they can be used to increase the production of vegetables in the state. Various medicinal plants will be conserved in the Biotech Park for research purposes. It has been learnt that the department is in the process of formulating the Biotech Policy for Bengal.

The state government has already taken the initiative to upgrade the infrastructure of Kolkata Biotech Park, apart from setting up new Biotechnology hubs in Burdwan and Kalimpong. The department has been focusing on the modernisation and expansion of the Common Instrument Facility Centre in the Biotech Park in the city. The department of Biotechnology will obtain all the necessary approvals and clearances to secure funding for the augmentation of the 'Bioincubator Facility' in Kolkata.

The department has a plan to conduct research on tissue culture to increase the yield and quality of various products but also to provide germ-free food to the common people. The Biotechnology department will tie up with other departments like Agriculture, Fisheries and Food Processing to strengthen organisational collaboration.

Better co-ordination with other departments will help the Biotechnology department to successfully implement the schemes. The department will help the Agriculture department to improve the quality of various fertilizers. It is also working to increase the production of fishes for the Fisheries department.

Tissue culture will be of immense help in increasing the productivity of land by enhancing crop quality, developing crops resistant to biotic and abiotic stresses, developing bio-fertilizers and bio-pesticides.

Bengal is rich in the biodiversity of crops, vegetables, fruits, flowers and other plant resources. The main objectives of the department are to provide better facilities to the common people and to improve the quality of life. It will also promote the overall development of both traditional and modern biotechnology in the state including various livelihood development programmes. It will also strengthen biotechnology-based aspects that will help in the development of the state economy from the grass-root level.

The Biotechnology department is applying specialised knowledge, skills and management to develop a viable and vibrant biotechnology-based industry in the state. It stresses on equitable and inclusive development through scientific means.

Read the original post:
Biotechnology dept to set up tissue culture lab - Millennium Post

Read More...

Biotechnology Summer Courses – Reach Cambridge

Tuesday, May 9th, 2017

The Reach Cambridge Biotechnology course introduces students to both the academic study of biotechnology and its exciting practical applications in the real world. This fast-growing area of modern science has the potential to fundamentally alter how we produce food, treat disease and create medicines. Topics covered include genetics, drug resistance, pharmaceutical science, biotechnological devices and drug design. Through lectures by experts in the field and hands-on practical sessions, students will be offered a unique insight into both the study of biotechnology at university and the vocational opportunities in the field beyond higher education.

This exciting and dynamic course will be a rewarding program for all those who have a passionate interest in biotechnology and biological sciences. During the Scholar program, the Biotechnology course is academically intensive and intellectually challenging, focused on the complex scientific problems which the discipline is in the process of tackling.

All Reach Cambridge courses are open to students aged between 14-18 years old.

All courses are taught in English. In order to get the most out of the learning experience, students are advised to have a level of English conducive to understanding sophisticated academic language and to converse with other students and staff in English at all times.

We do offer English as Second Language courses if you, or we, feel that this is more appropriate. Your personal statement will help indicate to us your level of English. We will also ask for a copy of your latest school transcript to help us assess the teaching level of the courses.

Originally posted here:
Biotechnology Summer Courses - Reach Cambridge

Read More...

BioTech Jobs in the BioTechnology Pharmaceuticals Industry

Tuesday, May 9th, 2017

1 - 15 of 6,981 jobs

Global Personnel Search Inc

Columbus, OH

Analytical ScientistColumbus, OHPosition Description:This Ph.D. Analytical Scientist (R&D) position will be responsible for leading the project from feasibility phase to commercial launch. We are...

posted 1 day ago

Bio Partners Search Group, LLC

Northern, Nj, NJ

The Associate Director, Commercial Analytics is responsible for supporting Marketing/Sales and Managed Care Markets Management in the following key areas: physician targeting, segmentation, sample...

posted 1 day ago

KOB Solutions, Inc.

Paramus, NJ

My client is actively recruiting for a Director of Clinical Operations to develop the internal infrastructure of this growing firm and oversee clinical trials operations. The ideal candidate will...

posted 1 day ago

Gallin Associates

Norristown, PA

Job Profile:Manager to oversee major key manufacturing transfer programs for a world class medical device manufacturer. The position will be responsible for managing the transfer of manufacturing...

posted 1 day ago

Med Exec Intl / MEIRxRS

Los Angeles, CA

VP Clinical & Regulatory Affairs needed in Los Angeles, CAVP Clinical and Regulatory Affairsneeded to develop and implement clinical studies and molecular diagnostics validation strategy. The...

posted 1 day ago

CHLOETA

Boise, ID

CHLOETA is a dynamic incident management firm that conducts and plans operations nationwide for a variety of public and private sector clients. Incident Management Team (IMT) ReservistAs an IMT...

posted 1 day ago

Regency Search Group

South Bend, IN

Company BackgroundFor 30 years, this research laboratory has been manufacturing and distributing a variety of enzymes and cofactors used in basic coagulation research. They are known and trusted by

posted 1 day ago

Spark Therapeutics, Inc

Philadelphia, PA

Individual with strong pharmacology and toxicology experience in developing AAV-based therapies. The candidate will be responsible for the strategy and execution of pharmacology and toxicology...

posted 2 days ago

Stabilis Professional Services

Andover, MA

Stabilis Professional Services, Inc. is looking for aBioinformatics Software Developer for their client in Andover, MA.Responsibilities: Designs, codes, tests, corrects and documents moderately...

posted 2 days ago

Excelsior Recruiting Group

New York, NY

BENEFITSCompetitive base starting at 90k plus commissionExcellent Benefits packageCompany CarGreat Growth Opportunity!!!QUALIFICATIONS Minimum of 10 years of sales & project experience in packaging

posted 3 days ago

Spark Therapeutics, Inc

Philadelphia, PA

The Research Scientist is a member of the Liver Discovery Research functional group within the Discovery Research group under Translational Research. He/she will be responsible for: Design and...

posted 4 days ago

Continental Search and Outplacement, Inc.

Indianapolis, IN

Leading company in animal agriculture seeks experienced sales professional to grow their market share in Indiana, Ohio and northern Kentucky. Candidates can live anywhere within the region andwork...

posted 4 days ago

Philadelphia, PA

The Assay Development Associate - Vector Shedding/Bio Distribution will: With guidance and supervision from the group leader or supervisor, conduct clinical and preclinical sample analysis per SOPs...

posted 4 days ago

Spark Therapeutics, Inc

Philadelphia, PA

The Sr. Regulatory Operations Specialist contributes to daily operations activities for preparation of regulatory submissions to FDA, EMA, and other key health authorities. They also collaborate...

posted 4 days ago

Spark Therapeutics, Inc

Philadelphia, PA

The Head of Medical Science Liaisons (MSL) will be responsible for helping to build and lead Spark MSL team(s). This position will define the objectives of the MSL function, including building...

posted 4 days ago

Originally posted here:
BioTech Jobs in the BioTechnology Pharmaceuticals Industry

Read More...

Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review – Los Angeles Business Journal

Monday, May 8th, 2017

Puma Biotechnology Inc.s stock took a dive last week after its regulatory executive resigned less than three weeks before a U.S. Food and Drug Administration panel is scheduled to review the public companys breast cancer drug Neratinib.

The Westwood companys share price dipped 14 percent to $31.38 at the close of business May 5 from $36.45 the day before, when the company notified the Securities and Exchange Commission that Robert Charnas, senior vice president of regulatory affairs and project management, would step down for health reasons effective May 15.

The stock was trading at $29.15 when the markets closed Monday.

The company, which has a market cap of $1.07 billion, hired 63-year-old Charnas last year with a base salary of more than $330,000, stock options, and a more than $378,000 signing bonus, according to the employment offer letter filed with the SEC.

An independent panel of experts is scheduled to review Neratinib for safety and efficacy May 24 before making a recommendation for its use to the FDA.

Caroline Anderson is a staff reporter covering retail, restaurants, and hospitality. She can be reached at canderson@labusinessjournal.com.

More here:
Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review - Los Angeles Business Journal

Read More...

ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain – Barron’s

Monday, May 8th, 2017

Barron's
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain
Barron's
Meanwhile the SPDR S&P Biotech ETF (XBI), the SPDR S&P Pharmaceuticals ETF (XPH), and the First Trust NYSE Arca Biotechnology Index (FBT) fell about 2.7% apiece. The AHCA could have both positive and negative impact on pharma and biotech, but ...

Follow this link:
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain - Barron's

Read More...

Animal Biotechnology Technologies, Markets and Companies 2016 … – PR Newswire (press release)

Monday, May 8th, 2017

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture.

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine.

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2016 is analyzed and the market is projected to 2026.

The text is supplemented with 35 tables and 5 figures.Selected 260 references from the literature are appended.

Key Topics Covered:

Executive Summary

1. Introduction to Animal Biotechnology

2. Application of Biotechnology in Animals

3. A Biotechnology Perspective of Animals Diseases

4. Molecular Diagnostics in Animals

5. Biotechnology-based Veterinary Medicine

6. Research in Animal Biotechnology

7. Animal Biotechnology Markets

8. Regulatory issues

9. Companies Involved in Animal Biotechnology

10. References

For more information about this report visit http://www.researchandmarkets.com/research/mdr33b/animal

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/animal-biotechnology-technologies-markets-and-companies-2016-2026-with-profiles-of-the-top-companies---research-and-markets-300452977.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Original post:
Animal Biotechnology Technologies, Markets and Companies 2016 ... - PR Newswire (press release)

Read More...

Page 50«..1020..49505152..6070..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick